Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.
Chamberlain SD, Wilson JW, Deanda F, Patnaik S, Redman AM, Yang B, Shewchuk L, Sabbatini P, Leesnitzer MA, Groy A, Atkins C, Gerding R, Hassell AM, Lei H, Mook RA Jr, Moorthy G, Rowand JL, Stevens KL, Kumar R, Shotwell JB. Chamberlain SD, et al. Bioorg Med Chem Lett. 2009 Jan 15;19(2):469-73. doi: 10.1016/j.bmcl.2008.11.046. Epub 2008 Nov 18. Bioorg Med Chem Lett. 2009. PMID: 19056263
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain SD, Redman AM, Wilson JW, Deanda F, Shotwell JB, Gerding R, Lei H, Yang B, Stevens KL, Hassell AM, Shewchuk LM, Leesnitzer MA, Smith JL, Sabbatini P, Atkins C, Groy A, Rowand JL, Kumar R, Mook RA Jr, Moorthy G, Patnaik S. Chamberlain SD, et al. Bioorg Med Chem Lett. 2009 Jan 15;19(2):360-4. doi: 10.1016/j.bmcl.2008.11.077. Epub 2008 Nov 24. Bioorg Med Chem Lett. 2009. PMID: 19071018
Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway.
Chamberlain SD, Redman AM, Patnaik S, Brickhouse K, Chew YC, Deanda F, Gerding R, Lei H, Moorthy G, Patrick M, Stevens KL, Wilson JW, Brad Shotwell J. Chamberlain SD, et al. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7. doi: 10.1016/j.bmcl.2008.11.065. Epub 2008 Nov 24. Bioorg Med Chem Lett. 2009. PMID: 19081716
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S, Stevens KL, Gerding R, Deanda F, Shotwell JB, Tang J, Hamajima T, Nakamura H, Leesnitzer MA, Hassell AM, Shewchuck LM, Kumar R, Lei H, Chamberlain SD. Patnaik S, et al. Among authors: chamberlain sd. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3136-40. doi: 10.1016/j.bmcl.2008.12.110. Epub 2009 Jan 6. Bioorg Med Chem Lett. 2009. PMID: 19394223
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Stevens KL, Alligood KJ, Alberti JG, Caferro TR, Chamberlain SD, Dickerson SH, Dickson HD, Emerson HK, Griffin RJ, Hubbard RD, Keith BR, Mullin RJ, Petrov KG, Gerding RM, Reno MJ, Rheault TR, Rusnak DW, Sammond DM, Smith SC, Uehling DE, Waterson AG, Wood ER. Stevens KL, et al. Among authors: chamberlain sd. Bioorg Med Chem Lett. 2009 Jan 1;19(1):21-6. doi: 10.1016/j.bmcl.2008.11.023. Epub 2008 Nov 13. Bioorg Med Chem Lett. 2009. PMID: 19028424
Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.
Stevens KL, Jung DK, Alberti MJ, Badiang JG, Peckham GE, Veal JM, Cheung M, Harris PA, Chamberlain SD, Peel MR. Stevens KL, et al. Among authors: chamberlain sd. Org Lett. 2005 Oct 13;7(21):4753-6. doi: 10.1021/ol0519745. Org Lett. 2005. PMID: 16209527
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.
Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, Kruger RG, Gontarek RR, Maksimchuk KR, Suravajjala S, Lapierre RR, Shotwell JB, Wilson JW, Chamberlain SD, Rabindran SK, Kumar R. Sabbatini P, et al. Among authors: chamberlain sd. Mol Cancer Ther. 2009 Oct;8(10):2811-20. doi: 10.1158/1535-7163.MCT-09-0423. Mol Cancer Ther. 2009. PMID: 19825801
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Emmitte KA, Adjabeng GM, Andrews CW, Alberti JG, Bambal R, Chamberlain SD, Davis-Ward RG, Dickson HD, Hassler DF, Hornberger KR, Jackson JR, Kuntz KW, Lansing TJ, Mook RA Jr, Nailor KE, Pobanz MA, Smith SC, Sung CM, Cheung M. Emmitte KA, et al. Among authors: chamberlain sd. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7. doi: 10.1016/j.bmcl.2009.01.094. Epub 2009 Jan 31. Bioorg Med Chem Lett. 2009. PMID: 19237286
The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M, Harris PA, Badiang JG, Peckham GE, Chamberlain SD, Alberti MJ, Jung DK, Harris SS, Bramson NH, Epperly AH, Stimpson SA, Peel MR. Cheung M, et al. Among authors: chamberlain sd. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5428-30. doi: 10.1016/j.bmcl.2008.09.040. Epub 2008 Sep 12. Bioorg Med Chem Lett. 2008. PMID: 18818075
35 results